6
Oct
2026
QILU PHARMACEUTICAL CO., LTD.
About QILU PHARMACEUTICAL CO., LTD.
Categories
Meet us at
-
CPHI Milan 2026
Fiera Milano, Italy
6 Oct 2026 - 8 Oct 2026stand 10C45, 5A73
-
Country/Region:China
-
On CPHI since:2015
-
Employees:5000+
Company types
Contact info
-
-
-
8888, Lvyou Road, High-Tech Zone, 250104, Jinan, China
Products from QILU PHARMACEUTICAL CO., LTD. (30)
-
Product Abaloparatide
Abaloparatide is a PTHrP(1-34) analog acting as an agonist at the PTH1 receptor (PTH1R). It activates the cAMP signaling pathway to stimulate osteoblastic activity and new bone formation. Administered as 80 mcg subcutaneously once daily. Abaloparatide demonstrates rapid and robust bone formation with the b... -
Product Aflibercept
Aflibercept is a VEGF trap fusion protein targeting VEGF-A, VEGF-B, and PIGF. As the second-largest anti-VEGF ophthalmology blockbuster, its extended q8w+ dosing in DME significantly reduces injection burden, with a mature biosimilar competitive landscape. -
Product Amphotericin B
Amphotericin B is a true single bilayer liposomal drug delivery system with amphotericin B intercalated within a liposomal membrane composed of hydrogenated soy phosphatidylcholine, distearoyl phosphatidylglycerol, and cholesterol. Liposomes are less than 100 nm in diameter. The liposomal encapsulation per... -
Product Aprepitant
Aprepitant, a highly selective neurokinin-1 receptor antagonist, provides superior protection against both acute and delayed chemotherapy-induced nausea and vomiting compared to conventional antiemetic agents, with a single dose offering sustained efficacy over many hours. Its ability to be combined with 5... -
Product Atezolizumab
Atezolizumab is an anti-PD-L1 mAb and the first approved for NSCLC first-line immunotherapy combinations. With differentiated positioning in urothelial carcinoma and HCC (combined with bevacizumab), it remains a significant competitor in the PD-L1 landscape. -
Product Bevacizumab
Bevacizumab is a humanized anti-VEGF-A mAb inhibiting tumor angiogenesis across multiple solid tumors. As the cornerstone anti-angiogenic agent with broad combination potential, it commands massive market volume with an established biosimilar competitive landscape. -
Product Bupivacaine
Bupivacaine utilizes proprietary DepoFoam technology to encapsulate bupivacaine within multivesicular liposomes, enabling sustained analgesia for up to 72 hours through a unique tri-phasic release mechanism involving initial burst, membrane diffusion, and particle erosion. This prolonged duration of action... -
Product Daratumumab
Daratumumab is an anti-CD38 mAb for multiple myeloma across all lines of therapy. From first-line to relapsed settings, its subcutaneous Faspro formulation compresses infusion from hours to minutes, making it the absolute cornerstone of MM treatment. -
Product Denosumab
Denosumab is a human anti-RANKL mAb; Prolia for osteoporosis and Xgeva for bone metastases. Its semiannual subcutaneous dosing offers superior compliance vs oral bisphosphonates, with dual-market positioning across orthopedics and oncology. -
Product Durvalumab
Durvalumab is an anti-PD-L1 mAb and the standard PACIFIC consolidation therapy for unresectable Stage III NSCLC post-chemoradiation. As the sole immunotherapy for limited-stage SCLC, its precise positioning in radiation-immunotherapy combinations sets the benchmark for locally advanced tumor care. -
Product Faricimab
Faricimab is the world's first bispecific antibody for ophthalmology, targeting both Ang-2 and VEGF-A. Enabling q16w dosing in DME/wAMD, it delivers a revolutionary compliance breakthrough and represents the next-generation blockbuster in retina. -
Product Ipratropium Bromide and Salbutamol
Ipratropium Bromide and Salbutamol is a combination of ipratropium bromide (anticholinergic) and albuterol sulfate (beta2-adrenergic agonist) delivered via the soft mist inhaler. It provides superior relief of bronchospasm compared to either agent alone in COPD patients with persistent symptoms despite reg...
QILU PHARMACEUTICAL CO., LTD. Resources (5)
-
Brochure Approved Biosimilars
Up to now, -
Brochure Approved Small Molecules
Up to now, there are a -
Brochure Small Molecules - R&D Pipeline
There are
